English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation

MPS-Authors
/persons/resource/persons147301

Sos,  Martin L.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Rode,  Haridas B.
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

/persons/resource/persons147194

Heynck,  Stefanie
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147255

Peifer,  Martin
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147167

Fischer,  Florian
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Klüter,  Sabine
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

Pawar,  Vijakumar G.
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

/persons/resource/persons147268

Reuter,  Cecile
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147193

Heuckmann,  Johannes M.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147338

Weiss,  Jonathan
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Ruddigkeit,  Lars
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

Rabiller,  Matthias
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

/persons/resource/persons147213

Koker,  Mirjam
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Simard,  Jeffrey R.
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

Getlik,  Matthäus
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

Yuza,  Yuki
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

Chen,  Tzu-Hsiu
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

Greulich,  Heidi
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

/persons/resource/persons147315

Thomas,  Roman K.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Rauh,  Daniel
1 Center of Integrated Oncology and Department I of Internal Medicine, University of Köln, Cologne, Germany; 2 Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany; 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan; 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 5 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 6 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts;

Locator
There are no locators available
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Sos, M. L., Rode, H. B., Heynck, S., Peifer, M., Fischer, F., Klüter, S., et al. (2010). Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research, 70(3), 868-874. doi:10.1158/0008-5472.CAN-09-3106.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0026-D307-E
Abstract
Copyright © 2010 by the American Association for Cancer Research